RCC
TAK icon

Red Cedar Capital’s Takeda Pharmaceutical TAK Stock Holding History

Red Cedar Capital’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,054
Closed -$54K – 150
2019
Q2 		$54K Hold
3,054
– – 0.05% 91
2019
Q1 		$62K Buy
+3,054
New +$61.5K 0.05% 86

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

Red Cedar Capital's TAK Position: Q3 2019 in Review

Red Cedar Capital sold out of Takeda Pharmaceutical (TAK) in Q3 2019, closing a stake of 3,054 shares — an estimated $54K sold.

Red Cedar Capital first reported a position in TAK in Q1 2019 and held it in 2 quarters. The position peaked at $62K in Q1 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

  • Red Cedar Capital reported no remaining Takeda Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • Red Cedar Capital sold 3,054 Takeda Pharmaceutical shares in Q3 2019, an estimated $54K.
  • Red Cedar Capital first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 2 quarters.
  • Red Cedar Capital's Takeda Pharmaceutical position peaked at $62K in Q1 2019.
  • 317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on Red Cedar Capital's 13F filing for Q3 2019, filed 22 Oct 2019.